Drug pricing policies are reshaping the life sciences landscape in many ways. From the United States’ Most-Favored-Nation (MFN) policy to evolving international frameworks, these decisions are influencing everything from commercialization strategies to investment valuations.

In this exclusive RBCx client webinar, industry experts David Dean, VP of Business Development at Eupraxia Pharmaceuticals Inc., Sarah Lawrie, Principal at Rosenblatt Life Science, Anne Woods, Managing Director, Life Sciences at RBCx and Abood Mohamed, VP, Life Sciences explore the global drug pricing models that matter most to your organization. You’ll gain practical insights into navigating pricing complexities, understanding regional policy impacts, and positioning your go-to-market approach for success in an evolving regulatory environment.

Whether you’re developing breakthrough therapies or guiding strategic investment decisions, this conversation offers the perspectives you need to move forward with confidence.

RBCx offers support to startups in all stages of growth, backing some of Canada’s most daring tech companies and idea generators. We turn our experience, networks, and capital into your competitive advantage to help you scale and make a meaningful impact on the world. Speak with an RBCx Advisor to learn more about how we can help your business grow.